Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.…
Bausch Health's Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide
Bausch Health Companies (NYSE: BHC) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 20,300 employees.
The shares were at 8.220 USD on 20 November 2026, up 35.9% over 52 weeks. Its 52-week range is 4.330 USD to 9.040 USD: the price is 9.1% below the high and 89.8% above the low.
Its market capitalisation is 3.08B USD.
Bausch Health Companies reports return on equity of -28.3%, an operating margin of 27.2% and revenue up 9.7% year over year.
Its debt exceeds its cash by 18.23B USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Hold; their mean price target of 8.400 USD is 2.2% above the current price. The next earnings report is expected on 17 February 2027.